任丽丽,赵昕,王丽,王效增,邓捷,邓宇阳,顾崇怀,韩雅玲

• 1:沈阳军区总医院全军心血管病研究所心内科

摘要(Abstract)：

目的评价接受经皮冠状动脉介入治疗(PCI)的急性ST段抬高心肌梗死(STEMI)患者应用磺达肝癸钠的临床疗效、安全性及预后。方法回顾性分析2010年3月至2011年7月沈阳军区总医院STEMI患者1184例,其中接受PCI的患者为1098例(磺达肝癸钠组527例及依诺肝素组571例),观察接受PCI的患者住院期间出血情况、院内再发心肌梗死发生率、冠状动脉病变特点及住院和随访期间(1个月)死亡率。结果接受PCI的磺达肝癸钠组与依诺肝素组比较:两组院内再发心肌梗死发生率[2.3%(12/527)比2.6%(15/571),P=0.708]、出院30 d死亡率[4.0%(21/527)比4.9%(28/571),P=0.387]差异无统计学意义,但磺达肝癸钠组院内大出血发生率显著降低[1.7%(9/527)比3.7%(21/571),P=0.045]且差异具有统计学意义。磺达肝癸钠组中替罗非班组(PCI术中应用替罗非班)的血流TIMI分级Ⅲ级获得率显著高于标准治疗组(PCI术中未应用替罗非班)[94.5%(206/218)比79.0%(244/309),P<0.001],但出血发生率两组间差异无统计学意义[1.83%(4/218)比1.62%(5/309),P=0.850]。两组住院及随访期间主要心血管事件发生率差异均无统计学意义(P均>0.05)。结论磺达肝癸钠对STEMI患者行PCI是安全的,联合替罗非班可以显著改善PCI术后的冠状动脉血流及临床预后,并且降低院内大出血风险。

关键词(KeyWords)： 冠状动脉疾病;磺达肝癸钠;血管成形术;经皮冠状动脉介入治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 任丽丽,赵昕,王丽,王效增,邓捷,邓宇阳,顾崇怀,韩雅玲

参考文献(References)：

• [1]Kadakia MB,Desai NR,Alexander KP,et al.Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction:a report from the NCDR ACTION Registry-GWTG(National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network RegistryGet With the Guidelines).JACC Cardiovasc Interv,2010,3:1166-1177.
• [2]Bassand JP,Hamm CW,Ardissino D,et al.Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.Rev Port Cardiol,2008,27:1063-1143.
• [3]The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen(ASSENT)-3 Investigators.Efficacy and safety of tenecteplase in combination with enoxaparin,abciximab,or unfractionated heparin:the ASSENT-3 randomised trial in acute myocardial infarction.Lancet,2001,358:605-613.
• [4]Puymirat E,Simon T,Steg PG,et al.Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction.JAMA,2012,308:998-1006.
• [5]朱梦云,于学靖,彭文辉,等.磺达肝癸钠对急性ST段抬高心肌梗死接受直接PCI患者的疗效和安全性研究.同济大学学报(医学版),2011,32:48-52.
• [6]刘广忠,李悦,李为民.冠状动脉多支血管病变血运重建功能性评价的新进展.中国介入心脏病学杂志,2013,21:322-325.
• [7]Wijns W,Kolh P,Danchin N,et a1.Guidelines on myocardial revascularization.Eur Heart J,2010,31:2501-2555.
• [8]Yusuf S,Mehta SR,Chrolavicius S,et a1.Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction:the OASIS-6 randomized trial.JAMA,2006,295:1519-1530.
• [9]Nagler M,Haslauer M,Wuillemin WA.Fondaparinux-data on efficacy and safety in special situations.Thromb Res,2012,129:407-417.
• [10]Li MW,Zhao XM,Rao LX,et al.The clinical efficacy and safety of fondaparinux combined with tirofiban hydrochloride in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention.Zhonghua Nei Ke Za Zhi,2013,52:1037-1040.
• [11]Steg PG,Jolly SS,Mehta SR et al.Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux:the FUTURA/OASIS-8 randomized trial.JAMA,2010,304:1339-1349.